U0126

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

U0126 是一种有效的选择性 MAP 激酶非竞争性抑制剂，抑制 MEK-1 和 MEK-2，IC50 值分别为 0.07 和 0.06 μM。 U0126 抑制自噬和线粒体自噬。

U0126, an effective and selective non-competitive inhibitor of MAP kinase, inhibits MEK-1 and MEK-2 with IC50 values of 0.07 and 0.06 μM respectively. U0126 inhibits autophagy and mitophagy.(In Vitro):Rat hepatocarcinoma cells (FAO) stimulated by fetal calf serum (FCS) exhibits a significant proportion in S phase (32.62%) whereas U0126 strongly decreases the proportion of cells in S phase (9.92%) and increases the proportion of cells in G0-G1 phase and to a lesser extent in G2/M. U0126 efficiently reduces progeny virus titers of all tested strains in A549 cells. While nM concentrations of U0126 are efficient to reduce H1N1v and H5N1 (MB1), μM concentrations of U0126 are required to reduce the virus titer of H5N1 (GSB) and H7N7. The EC50 values for U0126-EtOH against H1N1v are 1.2 μM in A549 cells and 74.7 μM in MDCKII cells.(In Vivo):In mice, U0126-EtOH (U0126; i.p., 10.5 mg/kg) inhibits tumor growth with a 60-70% reduction 9 days after injection and thereafter. After treatment with U0126-EtOH(U0126; i.p., 30 mg/kg), the vasoconstriction to S6c is markedly reduced in rats.

Treatment with U0126 efficiently reduces progeny virus titers of all tested strains in A549 cells. While nM concentrations of U0126 are efficient to reduce H1N1v and H5N1 (MB1), μM concentrations of U0126 are required to reduce the virus titer of H5N1 (GSB) and H7N7. The EC50 values for U0126-EtOH against H1N1v are 1.2±0.4 μM in A549 cells and 74.7±1.0 μM in MDCKII cells.Rat hepatocarcinoma cells (FAO) stimulated by fetal calf serum (FCS) exhibits a significant proportion in S phase (32.62%) whereas U0126 strongly decreases the proportion of cells in S phase (9.92%) and increases the proportion of cells in G0-G1 phase and to a lesser extent in G2/M. Cell Viability Assay Cell Line:A549 and MDCK II cells.Concentration:0.001-1000 μM.Incubation Time:48 h.Result:The EC50 values for U0126 against H1N1v were 1.2 ± 0.4 μM in A549 cells and 74.7 ± 1.0 μM in MDCKII cells

Mice are treated daily with U0126-EtOH (U0126; i.p., 10.5 mg/kg). In control experiment, tumor sizes are constant or slightly increase all over the kinetic. At the opposite, in all U0126-EtOH experiments, engraftment and early tumor growth are significantly decreased. Furthermore, a 60-70% reduction in the volume of tumors treated with U0126-EtOH is obtained 9 days after injection and thereafter. Rats are subjected to 120 minutes transient middle cerebral artery occlusion (tMCAO) and thereafter treated with the U0126-EtOH (U0126; i.p., 30 mg/kg) at 0 and 24 hours of reperfusion. After treatment with U0126-EtOH, the vasoconstriction to S6c is markedly reduced. Animal Model:Athymic female nude mice (SWISS, nu/nu).Dosage:10.5 mg/kg.Administration:Intraperitoneal injection daily.Result:Inhibited tumor growth.Animal Model:Twelve-week-old female Wistar rats (250 to 265 g) .Dosage:30 mg/kg.Administration:Intraperitoneally.Result:The vasoconstriction to S6c is markedly reduced.

U0126 | U 0126 | U-0126

Autophagy

Mitophagy

BTK

——

——

109511-58-2

380.49

C18H16N6S2

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (262.82 mM)

N\C(Sc1ccccc1N)=C(\C#N)/C(/C#N)=C(\N)Sc1ccccc1N

——

(-20℃)

With Ice Pack

≥ 2 years